BridgeBio Pharma Inc (BBIO)

BridgeBio Pharma (BBIO) Income Statement


BridgeBio Pharma Income Statement

Last quarter (Q4 2023), BridgeBio Pharma's total revenue was $1.75M, a decrease of -6.68% from the same quarter last year. In Q4, BridgeBio Pharma's net income was $-168.15M. See BridgeBio Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 9.30M$ 9.30M$ 77.65M$ 69.72M$ 8.25M$ 40.56M
Cost of Revenue
$ 1.85M$ 2.45M$ -3.43M$ 3.11M$ 0.00$ 2.50M
Gross Profit
$ 7.46M$ 6.86M$ 81.08M$ 66.60M$ 8.25M$ 38.06M
Operating Expense
$ 609.35M$ 608.75M$ 542.65M$ 643.23M$ 482.73M$ 304.30M
Operating Income
$ -600.47M$ -607.37M$ -512.20M$ -576.63M$ -474.48M$ -266.24M
Net Non Operating Interest Income Expense
$ -63.25M$ -63.25M$ -72.90M$ -45.65M$ -32.64M$ 150.00K
Other Income Expense
$ -17.97M$ -17.37M$ -100.45M$ -35.82M$ 1.63M$ -22.50M
Pretax Income
$ -654.55M$ -653.25M$ -477.78M$ -586.45M$ -505.49M$ -288.58M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -643.20M$ -643.20M$ -481.18M$ -562.54M$ -448.72M$ -260.59M
Basic EPS
$ -3.94$ -3.95$ -3.26$ -3.90$ -3.80$ -2.48
Diluted EPS
$ -3.94$ -3.95$ -3.26$ -3.90$ -3.80$ -2.48
Basic Average Shares
$ 651.17M$ 162.79M$ 147.47M$ 144.36M$ 118.00M$ 105.10M
Diluted Average Shares
$ 651.17M$ 162.79M$ 147.47M$ 144.36M$ 118.00M$ 105.10M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 612.50M$ 611.19M$ 539.22M$ 646.35M$ 482.73M$ 306.80M
Net Income From Continuing And Discontinued Operation
$ -643.20M$ -643.20M$ -481.18M$ -562.54M$ -448.72M$ -260.59M
Normalized Income
$ -397.93M$ -505.70M--$ -448.72M$ -260.59M
Interest Expense
----$ 36.66M$ 8.77M
$ -564.32M$ -571.96M$ -366.78M$ -539.68M$ -468.83M$ -279.82M
$ -407.93M$ -565.47M$ -360.01M$ -533.83M$ -467.38M$ -279.82M
Currency in USD

BridgeBio Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis